Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Comparative, Patient-blinded Study to Evaluate the Safety and Efficacy of G-CSF Alone Versus AMD3100 (240 µg/kg) Added to a G-CSF Mobilization Regimen in Adult Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkins Disease (HD) or Multiple Myeloma (MM) Who Have Previously Failed Stem Cell Collections or Collection Attempts
Conditions
Interventions
Plerixafor (AMD3100)
Can be any registered nonpegylated form of G-CSF
Locations
5
Germany
Berlin, Germany
Cologne, Germany
Dresden, Germany
Nuremberg, Germany
Würzburg, Germany
Start Date
November 1, 2007
Primary Completion Date
April 1, 2008
Completion Date
June 1, 2009
Last Updated
February 11, 2014
NCT05139017
NCT06337318
NCT07388563
NCT06263491
NCT05529069
NCT06189391
Lead Sponsor
Genzyme, a Sanofi Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions